Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04153929 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT04153929 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 413 participants.
The verdict
NCT04153929, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes. During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG BI 456906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2020-04-30 |
| Est. Completion | 2021-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04153929
The ClinicalTrials.gov registry entry for NCT04153929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04153929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04153929 about?
NCT04153929 is a clinical study titled "A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.". This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight. Participants are in the st...
What is the current status of trial NCT04153929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2020-04-30. Estimated completion is 2021-11-04.
What interventions are being tested in trial NCT04153929?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), BI 456906 (DRUG).
Who is sponsoring clinical trial NCT04153929?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.